Spyre Therapeutics, Inc.
SYRE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | -0.01 | 0.71 | 0.14 |
| FCF Yield | -14.38% | -67.31% | -211.42% | -17.38% |
| EV / EBITDA | -4.83 | -0.35 | -0.09 | -4.72 |
| Quality | ||||
| ROIC | -37.63% | -78.19% | -148.20% | -72.92% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.76 | 0.29 | 0.96 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -63.84% | – | – |
| Free Cash Flow Growth | -57.55% | -24.60% | -47.69% | 32.19% |
| Safety | ||||
| Net Debt / EBITDA | 0.43 | 0.82 | 0.37 | 0.16 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 58.77 | 15.87 |